Characterisation and Deposition Studies of Recrystallised Lactose from Binary Mixtures of Ethanol/butanol for Improved Drug Delivery from Dry Powder Inhalers

Overview

Journal AAPS J

Specialty Pharmacology

Date 2010 Nov 9

PMID 21057906

Citations 12

Authors

Waseem Kaialy

Gary P Martin

Martyn D Ticehurst

Paul Royall

Mohammad A Mohammad

John Murphy

Ali Nokhodchi

Affiliations

Soon will be listed here.

Abstract

Dry powder inhaler formulations comprising commercial lactose-drug blends can show restricted detachment of drug from lactose during aerosolisation, which can lead to poor fine particle fractions (FPFs) which are suboptimal. The aim of the present study was to investigate whether the crystallisation of lactose from different ethanol/butanol co-solvent mixtures could be employed as a method of altering the FPF of salbutamol sulphate from powder blends. Lactose particles were prepared by an anti-solvent recrystallisation process using various ratios of the two solvents. Crystallised lactose or commercial lactose was mixed with salbutamol sulphate and in vitro deposition studies were performed using a multistage liquid impinger. Solid-state characterisation results showed that commercial lactose was primarily composed of the α-anomer whilst the crystallised lactose samples comprised a α/β mixture containing a lower number of moles of water per mole of lactose compared to the commercial lactose. The crystallised lactose particles were also less elongated and more irregular in shape with rougher surfaces. Formulation blends containing crystallised lactose showed better aerosolisation performance and dose uniformity when compared to commercial lactose. The highest FPF of salbutamol sulphate (38.0 ± 2.5%) was obtained for the lactose samples that were crystallised from a mixture of ethanol/butanol (20:60) compared to a FPF of 19.7 ± 1.9% obtained for commercial lactose. Engineered lactose carriers with modified anomer content and physicochemical properties, when compared to the commercial grade, produced formulations which generated a high FPF.

Citing Articles

Improving Inhalation Performance with Particle Agglomeration via Combining Mechanical Dry Coating and Ultrasonic Vibration.

Zhang Q, Wang Z, Shi K, Zhou H, Wei X, Hall P Pharmaceutics. 2024; 16(1).

PMID: 38258079 PMC: 10821125. DOI: 10.3390/pharmaceutics16010068.

Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties.

Benke E, Farkas A, Szabo-Revesz P, Ambrus R Pharmaceutics. 2020; 12(6).

PMID: 32532040 PMC: 7356266. DOI: 10.3390/pharmaceutics12060535.

Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form.

Lam M, Ghafourian T, Nokhodchi A Drug Deliv Transl Res. 2019; 10(1):43-58.

PMID: 31286452 PMC: 6978301. DOI: 10.1007/s13346-019-00659-6.

Liqui-Pellet: the Emerging Next-Generation Oral Dosage Form Which Stems from Liquisolid Concept in Combination with Pelletization Technology.

Lam M, Ghafourian T, Nokhodchi A AAPS PharmSciTech. 2019; 20(6):231.

PMID: 31236781 PMC: 6591193. DOI: 10.1208/s12249-019-1441-9.

Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering.

Mehta P J Drug Deliv. 2018; 2018:5635010.

PMID: 29568652 PMC: 5820590. DOI: 10.1155/2018/5635010.

References

Guchardi R, Frei M, John E, Kaerger J . Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm. 2007; 348(1-2):10-7. DOI: 10.1016/j.ijpharm.2007.06.041. View

Ming Zeng X , Martin G, Marriott C, Pritchard J . The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate. Eur J Pharm Biopharm. 2001; 51(1):55-62. DOI: 10.1016/s0939-6411(00)00142-9. View

Dhumal R, Biradar S, Paradkar A, York P . Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 2008; 368(1-2):129-37. DOI: 10.1016/j.ijpharm.2008.10.006. View

Traini D, Young P, Thielmann F, Acharya M . The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev Ind Pharm. 2008; 34(9):992-1001. DOI: 10.1080/03639040802154889. View

Murtomaa M, Mellin V, Harjunen P, Lankinen T, Laine E, Lehto V . Effect of particle morphology on the triboelectrification in dry powder inhalers. Int J Pharm. 2004; 282(1-2):107-14. DOI: 10.1016/j.ijpharm.2004.06.002. View

Kaialy W, Martin G, Ticehurst M, Momin M, Nokhodchi A . The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int J Pharm. 2010; 392(1-2):178-88. DOI: 10.1016/j.ijpharm.2010.03.057. View

Zeng X, Pandhal K, Martin G . The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm. 2000; 197(1-2):41-52. DOI: 10.1016/s0378-5173(99)00400-7. View

Chew N, Chan H . Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res. 2002; 18(11):1570-7. DOI: 10.1023/a:1013082531394. View

Katainen J, Paajanen M, Ahtola E, Pore V, Lahtinen J . Adhesion as an interplay between particle size and surface roughness. J Colloid Interface Sci. 2006; 304(2):524-9. DOI: 10.1016/j.jcis.2006.09.015. View

10.

Zanen P, Go L, Lammers J . Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51(10):977-80. PMC: 472643. DOI: 10.1136/thx.51.10.977. View

11.

Kaialy W, Momin M, Ticehurst M, Murphy J, Nokhodchi A . Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Colloids Surf B Biointerfaces. 2010; 79(2):345-56. DOI: 10.1016/j.colsurfb.2010.04.016. View

12.

Iida K, Leuenberger H, Fueg L, Okamoto H, Danjo K . [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)]. Yakugaku Zasshi. 2000; 120(1):113-9. DOI: 10.1248/yakushi1947.120.1_113. View

13.

Telko M, Hickey A . Dry powder inhaler formulation. Respir Care. 2005; 50(9):1209-27. View

14.

Guenette E, Barrett A, Kraus D, Brody R, Harding L, Magee G . Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Int J Pharm. 2009; 380(1-2):80-8. DOI: 10.1016/j.ijpharm.2009.07.002. View

15.

STAHLHOFEN W, Gebhart J, Heyder J . Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J. 1980; 41(6):385-98a. DOI: 10.1080/15298668091424933. View

16.

Saunders M, Podluii K, Shergill S, Buckton G, Royall P . The potential of high speed DSC (hyper-DSC) for the detection and quantification of small amounts of amorphous content in predominantly crystalline samples. Int J Pharm. 2004; 274(1-2):35-40. DOI: 10.1016/j.ijpharm.2004.01.018. View

17.

Hoang Thi T, Danede F, Descamps M, Flament M . Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Eur J Pharm Biopharm. 2008; 70(1):380-8. DOI: 10.1016/j.ejpb.2008.04.002. View

18.

Labiris N, Dolovich M . Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003; 56(6):588-99. PMC: 1884307. DOI: 10.1046/j.1365-2125.2003.01892.x. View

19.

Tang P, Chan H, Chiou H, Ogawa K, Jones M, Adi H . Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets. Int J Pharm. 2008; 367(1-2):51-7. DOI: 10.1016/j.ijpharm.2008.09.024. View

20.

Adi S, Adi H, Tang P, Traini D, Chan H, Young P . Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci. 2008; 35(1-2):12-8. DOI: 10.1016/j.ejps.2008.05.009. View